In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
H.C. Wainwright adjusted its financial outlook for PepGen Inc. (NASDAQ:PEPG), reducing the price target to $16.00 from the ...
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...
KOIN Portland on MSN9h
Vancouver family launches son’s ashes into spaceA Vancouver family is sending their son on one final journey into the stars, where his ashes will eventually transform into a ...
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...
PepGen (PEPG) “provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy for patients ...
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...
Columnist Betty Vertin has learned that as a parent, she's finding the years with all her children, including those with DMD, too short.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback